Hyloris Pharmaceuticals SA

HYL

BE0974363955

Pharmaceuticals

Market Closed - Euronext Bruxelles Other stock markets 15:13:23 11/06/2026 BST			After hours 16:30:00
4.820 ^EUR	-2.03%		4.880	+1.24%

03-25	Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-20	Hyloris Pharmaceuticals Partners With Orion to Commercialize Gastric Acid Treatment	MT

Hyloris Pharmaceuticals : releases Annual Report 2025

Published on 04/30/2026 at 05:05 pm BST

Publicnow

HYLORIS PHARMACEUTICALS SA

-2.03%

30 Apr 2026 17:51 CEST

Issuer

HYLORIS PHARMACEUTICALS SA

hylorispress-releaseannual-report-2025en20260330.pdf

Source

HYLORIS

Provider

Euronext

Company Name

HYLORIS

ISIN

BE0974363955

Symbol

HYL

Market

Euronext

Company press releases subscription ×

To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or create an account.

Cancel

Attachments

Original document
Permalink

Disclaimer

Hyloris Developments SA published this content on April 30, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 30, 2026 at 16:04 UTC.

Latest news about Hyloris Pharmaceuticals SA

03-25	Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-20	Hyloris Pharmaceuticals Partners With Orion to Commercialize Gastric Acid Treatment	MT
12-31	Hyloris Secures European, Turkish License for ArborMed's Rare Disease Drug	MT
12-30	Hyloris Pharmaceuticals obtains exclusive license rights in Europe & Turkey from Arbormed for its Wilson's disease therapy	RE
12-30	Hyloris Pharmaceuticals, Rosemont Pharmaceuticals Sign US Licensing, Supply Deal for Atomoxetine Oral Solution	MT
12-29	Hyloris announces partnership with Rosemont Pharmaceuticals for atomoxetine oral solution in the U.S.	RE
12-12	Hyloris Pharmaceuticals, Wake Forest University to Develop Rare Skin Disorder Therapy	MT
11-19	Hyloris Pharmaceuticals Appoints Co-CEO as Sole Chief Executive	MT
27/10/25	Hyloris Pharmaceuticals Wins Exclusive Chinese Licensing, Distribution Deal for Iron Deficiency Anemia Treatment	MT
25/09/25	Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
23/06/25	Hyloris to Partially Fund Suramin IV Development for Sleeping Sickness	MT
22/06/25	Kuvatris Therapeutics, Inc. announced that it expects to receive $3.6 million in funding from Hyloris Pharmaceuticals SA	CI
04/06/25	Hyloris Partner Avenacy's Intravenous Tranexamic Acid Application Gets US FDA Nod	MT
22/05/25	Hyloris Pharmaceuticals Lands Exclusive Commercialization Deal for Xtraza Oral Rinse	MT
13/05/25	Hyloris Pharmaceuticals Signs Commercialization Deals for Valacyclovir	MT

Chart Hyloris Pharmaceuticals SA

Duration

Period

HYL: Dynamic Chart

Company Profile

Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company